Symbols / CYTK Stock $75.88 +1.43% Cytokinetics, Incorporated

Healthcare • Biotechnology • United States • NMS
CYTK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert I. Blum
Exch · Country NMS · United States
Market Cap 10.30B
Enterprise Value 9.93B
Income -829.61M
Sales 105.81M
FCF (ttm) -381.06M
Book/sh -6.65
Cash/sh 6.58
Employees 673
Insider 10d —
IPO Apr 30, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -15.62
PEG —
P/S 97.36
P/B -11.41
P/C —
EV/EBITDA -15.79
EV/Sales 93.88
Quick Ratio 4.14
Current Ratio 4.21
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -6.85
EPS next Y -4.86
EPS Growth —
Revenue Growth 11.26%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -31.54%
ROE —
ROIC —
Gross Margin -290.73%
Oper. Margin -9.49%
Profit Margin 0.00%
Shs Outstand 135.77M
Shs Float 123.88M
Insider Own 0.70%
Instit Own 115.81%
Short Float 20.84%
Short Ratio 9.34
Short Interest 15.90M
52W High 80.20
vs 52W High -5.39%
52W Low 29.31
vs 52W Low 158.89%
Beta 0.38
Impl. Vol. 66.55%
Rel Volume 0.07
Avg Volume 2.47M
Volume 171.00K
Target (mean) $105.00
Tgt Median $105.00
Tgt Low $69.00
Tgt High $146.00
# Analysts 19
Recom Buy
Prev Close $74.81
Price $75.88
Change 1.43%
About

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$105.00
Mean price target
2. Current target
$75.88
Latest analyst target
3. DCF / Fair value
$-50.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$75.88
Low
$69.00
High
$146.00
Mean
$105.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 main JP Morgan Overweight → Overweight $97
2026-05-11 main HC Wainwright & Co. Buy → Buy $140
2026-05-07 main Wells Fargo Overweight → Overweight $105
2026-05-06 main Stifel Buy → Buy $108
2026-05-06 main Morgan Stanley Overweight → Overweight $103
2026-05-06 main RBC Capital Outperform → Outperform $119
2026-05-05 main Needham Buy → Buy $102
2026-04-10 init Wells Fargo — → Overweight $95
2026-04-06 main Barclays Overweight → Overweight $95
2026-03-18 main Mizuho Outperform → Outperform $100
2026-03-17 main JP Morgan Overweight → Overweight $75
2026-03-06 main UBS Neutral → Neutral $69
2026-02-26 main Leerink Partners Outperform → Outperform $84
2026-02-25 main Citizens Market Outperform → Market Outperform $96
2026-02-25 main Needham Buy → Buy $85
2026-02-20 main RBC Capital Outperform → Outperform $101
2026-02-03 main Truist Securities Buy → Buy $92
2026-01-21 main B. Riley Securities Buy → Buy $108
2026-01-21 reit RBC Capital Outperform → Outperform $95
2026-01-20 main JP Morgan Overweight → Overweight $74
News
RSS: Latest CYTK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-05 LEE SUNG Chief Financial Officer — 23,906 $76.87 $1,837,654
2026-05-05 CALLOS ANDREW Officer — 11,333 $77.25 $875,474
2026-05-05 MALIK FADY IBRAHAM Officer — 3,500 $77.37 $270,795
2026-05-05 WIERENGA WENDELL Director — 4,032 $75.00 $302,400
2026-05-05 HENDERSON JOHN TANNAHILL Director — 20,000 $75.97 $1,519,400
2026-05-05 CALLOS ANDREW Officer — 11,333 $39.13 $443,460
2026-05-05 MALIK FADY IBRAHAM Officer — 3,500 $7.80 $27,300
2026-05-05 WIERENGA WENDELL Director — 4,032 $12.40 $49,997
2026-05-05 HENDERSON JOHN TANNAHILL Director — 20,000 $7.61 $152,200
2026-05-01 CALLOS ANDREW Officer — 15,857 $65.00 $1,030,705
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
88.04
+376.56%
18.47
+145.34%
7.53
-92.04%
94.59
Operating Revenue
88.04
+376.56%
18.47
+145.34%
7.53
-92.04%
94.59
Cost Of Revenue
416.03
+22.57%
339.41
+2.81%
330.12
+37.09%
240.81
Reconciled Cost Of Revenue
416.03
+22.57%
339.41
+2.81%
330.12
+37.09%
240.81
Gross Profit
-327.99
-2.20%
-320.93
+0.51%
-322.59
-120.61%
-146.22
Operating Expense
700.30
+26.24%
554.72
+10.12%
503.74
+20.28%
418.79
Research And Development
416.03
+22.57%
339.41
+2.81%
330.12
+37.09%
240.81
Selling General And Administration
284.27
+32.03%
215.31
+24.02%
173.61
-2.45%
177.98
General And Administrative Expense
284.27
+32.03%
215.31
+24.02%
173.61
-2.45%
177.98
Other Gand A
284.27
+32.03%
215.31
+24.02%
173.61
-2.45%
177.98
Total Expenses
700.30
+26.24%
554.72
+10.12%
503.74
+20.28%
418.79
Operating Income
-612.26
-14.17%
-536.25
-8.07%
-496.20
-53.05%
-324.20
Total Operating Income As Reported
-612.26
-14.17%
-536.25
-8.07%
-496.20
-53.05%
-324.20
EBITDA
-670.96
-35.96%
-493.48
-8.06%
-456.68
-37.56%
-331.99
Normalized EBITDA
-553.91
-11.95%
-494.78
-8.34%
-456.68
-48.73%
-307.05
Reconciled Depreciation
10.12
+6.23%
9.53
-19.85%
11.89
+104.54%
5.81
EBIT
-681.09
-35.40%
-503.01
-7.35%
-468.58
-38.71%
-337.80
Total Unusual Items
-117.05
-9103.77%
1.30
0.00
+100.00%
-24.94
Total Unusual Items Excluding Goodwill
-117.05
-9103.77%
1.30
0.00
+100.00%
-24.94
Special Income Charges
-121.25
0.00
0.00
+100.00%
-24.94
Other Special Charges
121.25
—
—
24.94
Net Income
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Pretax Income
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Net Non Operating Interest Income Expense
-55.45
-58.52%
-34.98
-16.44%
-30.04
+24.55%
-39.81
Interest Expense Non Operating
103.87
+20.06%
86.51
+50.02%
57.67
+12.73%
51.16
Net Interest Income
-55.45
-58.52%
-34.98
-16.44%
-30.04
+24.55%
-39.81
Interest Expense
103.87
+20.06%
86.51
+50.02%
57.67
+12.73%
51.16
Interest Income Non Operating
48.42
-6.04%
51.53
+86.52%
27.63
+143.60%
11.34
Interest Income
48.42
-6.04%
51.53
+86.52%
27.63
+143.60%
11.34
Other Income Expense
-117.25
-540.70%
-18.30
—
-24.94
Other Non Operating Income Expenses
-0.20
+98.98%
-19.60
—
—
Gain On Sale Of Security
4.20
+223.08%
1.30
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Net Income From Continuing Operation Net Minority Interest
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Net Income From Continuing And Discontinued Operation
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Net Income Continuous Operations
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Normalized Income
-667.91
-13.05%
-590.83
-12.27%
-526.24
-44.57%
-364.02
Net Income Common Stockholders
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Diluted EPS
-6.54
-24.33%
-5.26
+3.49%
-5.45
-25.87%
-4.33
Basic EPS
-6.54
-24.33%
-5.26
+3.49%
-5.45
-25.87%
-4.33
Basic Average Shares
120.10
+7.25%
111.98
+16.01%
96.52
+7.46%
89.83
Diluted Average Shares
120.10
+7.25%
111.98
+16.01%
96.52
+7.46%
89.83
Diluted NI Availto Com Stockholders
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,424.54
+1.63%
1,401.67
+70.04%
824.32
-18.77%
1,014.77
Current Assets
916.98
-17.24%
1,107.94
+76.41%
628.05
-21.02%
795.19
Cash Cash Equivalents And Short Term Investments
882.22
-18.01%
1,076.01
+75.01%
614.82
-21.44%
782.58
Cash And Cash Equivalents
122.52
+29.16%
94.86
-16.07%
113.02
+72.34%
65.58
Other Short Term Investments
759.70
-22.57%
981.16
+95.53%
501.80
-30.01%
717.00
Receivables
17.76
+6.69%
16.65
+1197.74%
1.28
+772.79%
0.15
Accounts Receivable
17.76
+6.69%
16.65
+1197.74%
1.28
+772.79%
0.15
Prepaid Assets
—
—
—
—
Other Current Assets
16.99
+11.22%
15.28
+27.90%
11.94
-4.16%
12.46
Total Non Current Assets
507.56
+72.80%
293.73
+49.66%
196.26
-10.62%
219.59
Net PPE
155.17
+10.07%
140.97
-4.58%
147.74
-9.47%
163.19
Gross PPE
202.47
+13.65%
178.15
+1.17%
176.08
-2.33%
180.28
Accumulated Depreciation
-47.30
-27.23%
-37.18
-31.15%
-28.35
-65.84%
-17.09
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
11.98
+27.17%
9.42
+1.05%
9.32
-6.35%
9.96
Construction In Progress
10.35
+154.51%
4.07
+1748.64%
0.22
-70.31%
0.74
Other Properties
99.94
+2.20%
97.79
-1.88%
99.67
-3.87%
103.67
Leases
80.20
+19.93%
66.87
+0.00%
66.87
+1.46%
65.91
Investments And Advances
335.05
+130.98%
145.06
+257.86%
40.53
-13.22%
46.71
Other Non Current Assets
17.34
+125.06%
7.71
-3.64%
8.00
-17.49%
9.69
Total Liabilities Net Minority Interest
2,084.16
+35.60%
1,537.05
+26.96%
1,210.64
+7.84%
1,122.67
Current Liabilities
202.45
+12.68%
179.67
+74.99%
102.68
+21.34%
84.62
Payables And Accrued Expenses
60.47
+49.08%
40.56
+16.24%
34.89
-27.22%
47.94
Payables
22.34
+9.66%
20.37
-5.29%
21.51
-16.02%
25.61
Accounts Payable
22.34
+9.66%
20.37
-5.29%
21.51
-16.02%
25.61
Current Accrued Expenses
38.13
+88.84%
20.19
+50.84%
13.39
-40.05%
22.33
Pensionand Other Post Retirement Benefit Plans Current
45.15
+28.52%
35.13
+20.09%
29.25
+34.40%
21.77
Current Debt And Capital Lease Obligation
60.29
+97.69%
30.50
+9.03%
27.97
+102.88%
13.79
Current Debt
41.18
+257.47%
11.52
+14.29%
10.08
+952.19%
0.96
Other Current Borrowings
41.18
+257.47%
11.52
+14.29%
10.08
+952.19%
0.96
Current Capital Lease Obligation
19.11
+0.70%
18.98
+6.08%
17.89
+39.46%
12.83
Current Deferred Liabilities
1.61
-96.92%
52.37
0.00
—
Current Deferred Revenue
1.61
-96.92%
52.37
0.00
—
Other Current Liabilities
34.93
+65.45%
21.11
+99.96%
10.56
+840.25%
1.12
Total Non Current Liabilities Net Minority Interest
1,881.71
+38.63%
1,357.37
+22.51%
1,107.96
+6.73%
1,038.06
Long Term Debt And Capital Lease Obligation
1,223.95
+61.43%
758.18
+4.17%
727.80
-1.18%
736.51
Long Term Debt
1,115.98
+72.86%
645.60
+6.29%
607.37
-0.37%
609.62
Long Term Capital Lease Obligation
107.97
-4.10%
112.58
-6.51%
120.43
-5.10%
126.89
Non Current Deferred Liabilities
—
—
—
0.00
Non Current Deferred Revenue
—
—
—
0.00
Other Non Current Liabilities
657.76
+9.77%
599.19
+57.62%
380.16
+26.07%
301.55
Stockholders Equity
-659.62
-387.27%
-135.37
+64.96%
-386.32
-258.04%
-107.90
Common Stock Equity
-659.62
-387.27%
-135.37
+64.96%
-386.32
-258.04%
-107.90
Capital Stock
0.12
+4.24%
0.12
+15.69%
0.10
+8.51%
0.09
Common Stock
0.12
+4.24%
0.12
+15.69%
0.10
+8.51%
0.09
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
122.94
+4.00%
118.21
+16.30%
101.64
+7.17%
94.83
Ordinary Shares Number
122.94
+4.00%
118.21
+16.30%
101.64
+7.17%
94.83
Additional Paid In Capital
2,826.34
+10.24%
2,563.88
+48.56%
1,725.82
+16.48%
1,481.59
Retained Earnings
-3,486.72
-29.05%
-2,701.76
-27.91%
-2,112.24
-33.18%
-1,585.99
Gains Losses Not Affecting Retained Earnings
0.63
-73.73%
2.40
+24080.00%
-0.01
+99.72%
-3.59
Other Equity Adjustments
0.63
-73.73%
2.40
+24080.00%
-0.01
+99.72%
-3.59
Total Equity Gross Minority Interest
-659.62
-387.27%
-135.37
+64.96%
-386.32
-258.04%
-107.90
Total Capitalization
456.36
-10.56%
510.23
+130.82%
221.05
-55.94%
501.72
Working Capital
714.52
-23.03%
928.27
+76.69%
525.37
-26.06%
710.57
Invested Capital
497.54
-4.64%
521.75
+125.74%
231.13
-54.02%
502.68
Total Debt
1,284.24
+62.84%
788.68
+4.35%
755.77
+0.73%
750.30
Net Debt
1,034.64
+84.02%
562.26
+11.46%
504.43
-7.44%
544.99
Capital Lease Obligations
127.08
-3.40%
131.56
-4.89%
138.32
-1.01%
139.72
Net Tangible Assets
-659.62
-387.27%
-135.37
+64.96%
-386.32
-258.04%
-107.90
Tangible Book Value
-659.62
-387.27%
-135.37
+64.96%
-386.32
-258.04%
-107.90
Available For Sale Securities
335.05
+130.98%
145.06
+257.86%
40.53
-13.22%
46.71
Investmentin Financial Assets
335.05
+130.98%
145.06
+257.86%
40.53
-13.22%
46.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-510.01
-28.83%
-395.89
+4.45%
-414.33
-38.33%
-299.52
Cash Flow From Continuing Operating Activities
-510.01
-28.83%
-395.89
+4.45%
-414.33
-38.33%
-299.52
Net Income From Continuing Operations
-784.96
-33.15%
-589.53
-12.03%
-526.24
-35.30%
-388.95
Depreciation Amortization Depletion
10.12
+6.23%
9.53
-19.85%
11.89
+104.54%
5.81
Depreciation
10.12
+6.23%
9.53
-19.85%
11.89
+104.54%
5.81
Depreciation And Amortization
10.12
+6.23%
9.53
-19.85%
11.89
+104.54%
5.81
Other Non Cash Items
192.39
+270.87%
51.88
+108.92%
24.83
-56.95%
57.68
Stock Based Compensation
112.29
+14.76%
97.84
+35.77%
72.06
+50.60%
47.85
Asset Impairment Charge
—
—
0.00
0.00
Operating Gains Losses
-4.22
-231.63%
-1.27
-3740.00%
0.04
-98.75%
2.80
Gain Loss On Investment Securities
-4.22
-220.32%
-1.32
-3868.57%
0.04
-67.29%
0.11
Gain Loss On Sale Of PPE
0.00
-100.00%
0.04
0.00
0.00
Change In Working Capital
-35.63
-199.90%
35.66
+1054.55%
3.09
+112.50%
-24.70
Change In Receivables
-1.11
+92.75%
-15.37
-1252.73%
-1.14
-102.00%
56.67
Changes In Account Receivables
-1.11
+92.75%
-15.37
-1252.73%
-1.14
-102.00%
56.67
Change In Prepaid Assets
-2.93
-20.30%
-2.44
-252.76%
1.60
+121.53%
-7.41
Change In Payables And Accrued Expense
36.27
+273.91%
9.70
-28.79%
13.62
-11.37%
15.37
Change In Accrued Expense
33.60
+136.94%
14.18
-17.08%
17.10
+57.72%
10.84
Change In Payable
2.66
+159.40%
-4.48
-28.71%
-3.48
-176.99%
4.52
Change In Account Payable
2.66
+159.40%
-4.48
-28.71%
-3.48
-176.99%
4.52
Change In Other Working Capital
-50.76
-196.92%
52.37
—
-87.00
Change In Other Current Liabilities
-17.09
-98.71%
-8.60
+21.75%
-10.99
-371.72%
-2.33
Investing Cash Flow
16.67
+103.01%
-553.10
-331.18%
239.25
+191.27%
-262.13
Cash Flow From Continuing Investing Activities
16.67
+103.01%
-553.10
-331.18%
239.25
+191.27%
-262.13
Net PPE Purchase And Sale
-24.81
-535.10%
-3.91
-175.85%
-1.42
+87.51%
-11.34
Purchase Of PPE
-24.81
-535.10%
-3.91
-175.85%
-1.42
+87.51%
-11.34
Capital Expenditure
-24.81
-535.10%
-3.91
-175.85%
-1.42
+87.51%
-11.34
Net Investment Purchase And Sale
41.47
+107.55%
-549.19
-328.19%
240.67
+195.96%
-250.80
Purchase Of Investment
-1,068.17
+17.41%
-1,293.42
-103.62%
-635.21
+25.74%
-855.39
Sale Of Investment
1,109.65
+49.10%
744.23
-15.03%
875.88
+44.87%
604.59
Financing Cash Flow
524.46
-43.64%
930.61
+320.49%
221.32
-57.12%
516.17
Cash Flow From Continuing Financing Activities
524.46
-43.64%
930.61
+320.49%
221.32
-57.12%
516.17
Net Issuance Payments Of Debt
315.95
+3384.96%
-9.62
-1020.98%
-0.86
-100.26%
334.66
Issuance Of Debt
729.46
0.00
0.00
-100.00%
523.59
Repayment Of Debt
-413.51
-4199.37%
-9.62
-1020.98%
-0.86
+99.55%
-188.93
Long Term Debt Issuance
729.46
0.00
0.00
-100.00%
523.59
Long Term Debt Payments
-413.51
-4199.37%
-9.62
-1020.98%
-0.86
+99.55%
-188.93
Net Long Term Debt Issuance
315.95
+3384.96%
-9.62
-1020.98%
-0.86
-100.26%
334.66
Net Common Stock Issuance
0.00
-100.00%
706.84
+330.39%
164.23
0.00
Proceeds From Stock Option Exercised
35.98
-32.14%
53.02
+187.21%
18.46
+5.22%
17.54
Net Other Financing Charges
172.53
-4.34%
180.37
+356.83%
39.48
-75.92%
163.96
Changes In Cash
31.11
+269.32%
-18.38
-139.74%
46.24
+201.66%
-45.48
Effect Of Exchange Rate Changes
-0.71
-442.11%
0.21
+1145.00%
-0.02
0.00
Beginning Cash Position
95.23
-16.02%
113.40
+68.79%
67.18
-40.37%
112.67
End Cash Position
125.63
+31.92%
95.23
-16.02%
113.40
+68.79%
67.18
Free Cash Flow
-534.82
-33.77%
-399.80
+3.84%
-415.75
-33.75%
-310.85
Interest Paid Supplemental Data
22.91
-11.77%
25.97
+152.26%
10.29
-32.11%
15.16
Common Stock Issuance
0.00
-100.00%
706.84
+330.39%
164.23
0.00
Issuance Of Capital Stock
0.00
-100.00%
706.84
+330.39%
164.23
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category